The dwindling number of amyloid-targeting drugs in development for Alzheimer’s disease (AD) has been reduced by one more, after Biogen and Eisai pulled the plug on aducanumab.
Japan’s Eisai has a long-term commitment to treating epilepsy, with a series of therapies already on the market - but with many different forms of the disease, requiring different therapeutic appro
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
